Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
CIO Summit: The CIO's Role in Advancing Customer-led Business Transformation Will Drive the Dialogue at HMG Strategy's Upcoming Greenwich CIO Conference

As company leaders look to transform their businesses to better attune to the preferences and needs of its customers, CIOs and technology executives play a critical role in identifying how technology can...

IBM : 149.97 (+0.61%)
JNJ : 140.52 (+0.04%)
PRGO : 73.91 (+0.79%)
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 16th, to review third-quarter results. Joseph J. Wolk, Executive Vice President,...

JNJ : 140.52 (+0.04%)
J&J Files NDA for Erdafitinib in Urothelial Cancer Indication

Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking approval of pan-FGFR inhibitor, erdafitinib, for the treatment of metastatic urothelial cancer, a type of bladder cancer.

JNJ : 140.52 (+0.04%)
MRK : 69.98 (-0.62%)
LLY : 105.74 (-1.07%)
PFE : 43.41 (+0.35%)
Aduro's Cancer Arm & Strong Collaborations Boost Growth

Aduro focuses on a broad pipeline of novel immunotherapies, developed for treating various types of cancers. Its collaboration agreements with large pharma companies fetch in regular funds.

JNJ : 140.52 (+0.04%)
NVS : 84.66 (-0.28%)
ADRO : 6.40 (-5.19%)
BMY : 60.80 (-1.11%)
Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Erdafitinib for the Treatment of Metastatic Urothelial Cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of erdafitinib...

JNJ : 140.52 (+0.04%)
Cerus Endovascular Strengthens Board of Directors with Appointment of John T. Kilcoyne

Cerus Endovascular Ltd., a privately held, commercial-stage medical device company engaged in the design and development of highly differentiated and proprietary interventional neuroradiology devices and...

JNJ : 140.52 (+0.04%)
Tyme Appoints Accomplished Healthcare Executive Douglas A. Michels to Board of Directors

-- Former OraSure Technologies President and CEO and Johnson and Johnson executive to join Tyme board of directors

OSUR : 15.52 (+0.32%)
JNJ : 140.52 (+0.04%)
TYME : 2.79 (+4.10%)
CISCRP Releases New Video on Initiative to Improve Diversity in Clinical Research

The Center for Information and Study on Clinical Research Participation (CISCRP), a Boston-based nonprofit organization, announces a new video featuring an innovative program to increase awareness and...

JNJ : 140.52 (+0.04%)
Relatively Good Performance Detected in Shares of Bristol-Myer Sqb in the Pharmaceuticals Industry (BMY , MRK , JNJ , PFE , DERM )

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

JNJ : 140.52 (+0.04%)
MRK : 69.98 (-0.62%)
BMY : 60.80 (-1.11%)
Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV

Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.

JNJ : 140.52 (+0.04%)
LLY : 105.74 (-1.07%)
GSK : 39.52 (-0.08%)
PFE : 43.41 (+0.35%)
Pfizer's Skin Disease Candidates Positive in Mid-Stage Study

Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.

JNJ : 140.52 (+0.04%)
ABBV : 91.00 (-0.02%)
RHHBY : 30.5500 (-0.39%)
PFE : 43.41 (+0.35%)
Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

JNJ : 140.52 (+0.04%)
Is Artificial Intelligence the Next Big Thing in Biotech?

Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.

AZN : 37.50 (+0.54%)
JNJ : 140.52 (+0.04%)
NVS : 84.66 (-0.28%)
RHHBY : 30.5500 (-0.39%)
GSK : 39.52 (-0.08%)
PFE : 43.41 (+0.35%)
SNY : 43.84 (-0.14%)
First Randomized Controlled Trial in Portopulmonary Hypertension Shows OPSUMIT(R) (macitentan) Significantly Improved Pulmonary Vascular Resistance Compared with Placebo

Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has announced the results of the first randomized controlled trial in portopulmonary hypertension...

JNJ : 140.52 (+0.04%)
Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus

Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week

AZN : 37.50 (+0.54%)
JNJ : 140.52 (+0.04%)
MRK : 69.98 (-0.62%)
LLY : 105.74 (-1.07%)
PFE : 43.41 (+0.35%)
GSK : 39.52 (-0.08%)
BMY : 60.80 (-1.11%)
Pharma/Biotech Stocks to Watch This Prostate Cancer Month

Here we highlight a few companies that are focused on developing treatments for prostate cancer.

AZN : 37.50 (+0.54%)
JNJ : 140.52 (+0.04%)
ECYT : 17.54 (-2.39%)
ABBV : 91.00 (-0.02%)
TSRO : 37.00 (-0.03%)
PFE : 43.41 (+0.35%)
SNY : 43.84 (-0.14%)
Skincare Products Market - Rise in Demand for Anti-ageing Products to be the Key Growth Factor; TMR

According to the report, the global skincare products market had a net valuation of US$110.69 bn in 2014. Exhibiting a moderate 4.9% CAGR between 2015 and 2021, the market is expected to rise to a revenue...

JNJ : 140.52 (+0.04%)
PG : 84.40 (+0.48%)
MorphoSys Announces That its Licensee Janssen has Reported That Tremfya(R) Improves Long-Term Patient-Reported Outcomes in Patients with Moderate to Severe Plaque Psoriasis

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / September 13, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Pharmaceutical Companies of Johnson...

MOR : 27.36 (+1.07%)
MPSYY : 27.9300 (+0.87%)
JNJ : 140.52 (+0.04%)
Johnson & Johnson Medical GmbH Acquires Emerging Implant Technologies GmbH to Enhance Global Offering of Interbody Spine Implants

Johnson & Johnson Medical Devices Companies*, through its subsidiary Johnson & Johnson Medical GmbH, announced today the acquisition of Emerging Implant Technologies GmbH (EIT), a privately held manufacturer...

JNJ : 140.52 (+0.04%)
Janssen's TREMFYA(R) Improves Long-Term Patient-Reported Outcomes in Patients with Moderate to Severe Plaque Psoriasis

--Patient-reported symptom-free status shown to be a better indicator of quality of life improvement than The Psoriasis Area and Severity Index (PASI) 100 response

JNJ : 140.52 (+0.04%)

Van Meerten Stock Picks

Tesla According to Peter Lynch
Today's Barchart Chart of the Day will be the auto maker Tesla (TSLA).
TSLA +4.31
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

cmdty Insider - Ag Market Commentary

Today's Commentary

Corn futures are trading fractionally higher since ending the Wednesday session with most contracts 2 to 3 cents in the green. Preliminary open interest rose 17,242 contracts as harvest expands. The weekly EIA report indicated that ethanol plants pro...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar